The Molecule of the Month series explores the functions and
significance of selected biological macromolecules for a general
audience. These features, written and illustrated by Dr. David
S. Goodsell of the Scripps Research Institute, are available at
A sample of the molecules featured during this past quarter are included below:
PDB ID: 1tup
Cho, Y., Gorina, S., Jeffrey, P. D., Pavletich, N. P. (1994): Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265, pp. 346.
PDB ID: 1ycq
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., Pavletich, N. P. (1996): Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, pp. 948.
July, 2002 -- Our cells face many dangers, including chemicals, viruses, and ionizing radiation. If cells are damaged in sensitive
places by these attackers, the effects can be disastrous. For instance, if key regulatory elements are damaged, the normal
controls on cell growth may be blocked and the cell will rapidly multiply and grow into a tumor. p53 tumor suppressor is one of
our defenses against this type of damage. p53 tumor suppressor is normally found at low levels, but when DNA damage is
sensed, p53 levels rise and initiate protective measures. p53 binds to many regulatory sites in the genome and begins
production of proteins that halt cell division until the damage is repaired. Or, if the damage is too severe, p53 initiates the
process of programmed cell death, or apoptosis, which directs the cell to commit suicide, permanently removing the damage.
p53 tumor suppressor is a flexible molecule composed of four identical protein chains. Flexible molecules are difficult to study
by X-ray crystallography because they do not form orderly crystals, and if they do crystallize, the experimental images are often
blurry. So, p53 has been studied in parts, by removing the flexible regions and solving structures of the pieces that form stable
structures. Three of these compact, globular portions, termed "domains", have been studied. At the center of p53 is a
tetramerization domain (PDB entry 1olg) that ties the four chains together. A long flexible region in each chain then connects to
the second stable domain: a large DNA-binding domain (PDB entry 1tup) that is rich in arginine residues that interact with DNA.
This domain recognizes specific regulatory sites on the DNA. The third stable domain studied thus far is the transactivation
domain (PDB entry 1ycq), found near the end of each arm, that activates the DNA-reading machinery.
As you might guess from its name, p53 tumor suppressor plays a central role in the protection of your body from cancer.
Cancer cells typically contain two types of mutations: mutations that cause uncontrolled growth and multiplication of cells,
and other mutations that block the normal defenses that protect against unnatural growth. p53 is in this second category and
mutations in the p53 gene contribute to about half of the cases of human cancer. Most of these are missense mutations,
changing the information in the DNA at one position and causing the cell to build p53 with an error, swapping an incorrect
amino acid at one point in the protein chain. In these mutants, the normal function of p53 is blocked and the protein is unable
to stop multiplication in the damaged cell. If the cell has other mutations that cause uncontrolled growth, the cell will develop
into a tumor.
Further information about p53 tumor suppressor can be found at
Chaperones: Guides Along the Folding Pathway
August, 2002 -- As you can see when looking through the many structures in the PDB, most active proteins have a stable,
globular structure. However, proteins are built as formless chains, pieced together one amino acid at a time by ribosomes.
Most protein chains then fold spontaneously into their final structure, driven by the need to shelter their carbon-rich portions
from the surrounding water. But some--large proteins or proteins with several domains--need some assistance. As they fold
into a compact shape, they might get stuck somewhere along the way.
This is not a trivial problem. Cells cannot merely wait for proteins to fold properly. Misfolded proteins often have carbon-rich
amino acids on their surfaces, instead of tucked safely inside. These carbon-rich patches associate strongly with similar
patches on other proteins, forming large aggregates. Random aggregates are death to cells: diseases such as sickle cell
anemia, mad cow disease, and Alzheimer's disease are caused by unnatural aggregations of proteins into cell-clogging
Chaperones are proteins that guide proteins along the proper pathways for folding. They protect proteins when they are in
the process of folding, shielding them from other proteins that might bind and hinder the process. Many chaperone
proteins are termed "heat shock" proteins (with names like HSP-60) because they are made in large amounts when
cells are exposed to heat. Heat, in general, destabilizes proteins and makes misfolding more common. So when it
gets really hot, cells need some extra help with their proteins.
One impressive type of chaperone forms an enclosed environment for folding proteins which totally protects them as they
fold. The GroEL-GroES complex of the bacterium E. coli can be seen in PDB entry 1aon. It is composed of two stacked
rings of GroEL proteins, and a cap on one side composed of GroES. Seven GroEL proteins form a ring with a protein-sized
cavity inside. Unfolded proteins enter this cavity and fold up inside.
Further information about chaperones can be found at
Reverse Transcriptase: A Sloppy Enzyme
September, 2002 -- Viruses are tricky. They use all sorts of unusual mechanisms during their attacks on cells. HIV is no
exception. It is a retrovirus, which means that it has the ability to insert its genetic material into the genome of the cells that
it infects. But, infectious HIV particles carry their genome in RNA strands. Somehow, during infection, the virus needs to
make a DNA copy of its RNA genome. This is very unusual, because all of the normal cellular machinery is designed to
make RNA copies from DNA, but not the reverse. DNA is normally only created using other DNA strands as a template.
This tricky reversal of synthesis is performed by the enzyme reverse transcriptase, as found in PDB entry 3hvt. Inside its
large, claw-shaped active site, it copies the HIV RNA and creates a double-stranded DNA version of the viral genome. This
then integrates into the cell's DNA, and later instructs the cell to make additional copies of the virus.
Viruses are tiny. They only carry enough genetic material to encode a few proteins. Many viruses, such as poliovirus and
rhinovirus, carry the bare minimum--just enough to specify their own structure and get synthesis started once they get
inside cells. The genome of HIV, on the other hand, carries instructions for building a few enzymes that are used in the
reproduction of the virus. Reverse transcriptase is one of these enzymes. But, space in the HIV genome is still at a
premium, so reverse transcriptase is encoded in a tricky way. It is composed of two different subunits, but both are
encoded by the same gene. After the protein is made, one of the subunits is clipped to a smaller size so that it can
form the proper mate with one full-sized subunit.
Reverse transcriptase performs a remarkable feat, reversing the normal flow of genetic information, but it is rather sloppy
in its job. The polymerases used to make DNA and RNA in cells are very accurate and make very few mistakes. This is
essential because they are the caretakers of our genetic information, and mistakes may be passed on to our offspring.
Reverse transcriptase, on the other hand, makes lots of mistakes, up to about one in every 2,000 bases that it copies
(if this same error rate occurred in the "Molecule of the Month," there would be two typos in this month's installment).
You might think that this would cause severe problems. But, in fact, this high error rate turns out to be an advantage
for the virus in this era of drug treatment. The errors allow HIV to mutate rapidly, finding drug resistant strains in a
matter of weeks after treatment begins. Fortunately, the recent development of treatments that combine several
drugs are often effective in combating this problem. Since the virus is simultaneously attacked by several different
drugs, it cannot mutate to evade all of them at the same time.
Further information about reverse transcriptase can be found at
The RCSB PDB (citation) is managed by two members of the Research Collaboratory for Structural Bioinformatics:
RCSB PDB is a member of the
The RCSB PDB is funded by a grant (DBI-1338415) from the
National Science Foundation, the
National Institutes of Health, and the
US Department of Energy.